Editas Medicine (EDIT) Cash from Financing Activities (2015 - 2025)
Editas Medicine (EDIT) reported Cash from Financing Activities of $17.2 million for Q3 2025, up 131.64% quarter-over-quarter from $7.4 million in Q2 2025.
Editas Medicine (EDIT) Cash from Financing Activities (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 11 years of Cash from Financing Activities data on file, last reported at $17.2 million in Q3 2025.
- Cash from Financing Activities for Q3 2025 came in at $17.2 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $78.7 million (up 7551.46% YoY), and the FY2024 annual result was $56.0 million, down 52.54% from the prior year.
- Cash from Financing Activities advanced to $17.2 million in Q3 2025 per EDIT's latest filing, from $7.4 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $261.5 million in Q1 2021 and troughed at -$1.4 million in Q1 2025.
- A 5-year average of $30.0 million and a median of $838000.0 in 2021 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities surged 31923.16% in 2023, then tumbled 848.44% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $1.1 million in 2021, then slumped by 41.44% to $619000.0 in 2022, then retreated by 16.96% to $514000.0 in 2023, then jumped by 10700.19% to $55.5 million in 2024, then sank by 69.07% to $17.2 million in 2025.
- Business Quant data shows EDIT's Cash from Financing Activities at $17.2 million in Q3 2025, $7.4 million in Q2 2025, and -$1.4 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 17.17 Mn |
| Sep 30, 2025 | 17.17 Mn |
| Jun 30, 2025 | 7.41 Mn |
| Jun 30, 2025 | 7.41 Mn |
| Mar 31, 2025 | -1.44 Mn |
| Mar 31, 2025 | -1.44 Mn |
| Dec 31, 2024 | 55.51 Mn |
| Dec 31, 2024 | 55.51 Mn |
| Jun 30, 2024 | 322,000.00 |
| Jun 30, 2024 | 322,000.00 |
| Mar 31, 2024 | 192,000.00 |
| Mar 31, 2024 | 192,000.00 |
| Dec 31, 2023 | 514,000.00 |
| Dec 31, 2023 | 514,000.00 |
| Jun 30, 2023 | 117.53 Mn |
| Jun 30, 2023 | 117.53 Mn |
| Dec 31, 2022 | 619,000.00 |
| Dec 31, 2022 | 619,000.00 |
| Sep 30, 2022 | 80,000.00 |
| Sep 30, 2022 | 80,000.00 |